Futura Medical plc

Good morning and welcome to the Futura Medical PLC Infant Results Investor Presentation. Throughout this quarter's presentation, investors will be in listen-only mode. Questions are encouraged and can be submitted at any time by the Q&A tab situated in the right corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all the questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand it to James Barter, CEO. Good morning, sir.

Good morning, everyone, and welcome to Futura Medical's interim results presentation for the period ending 30 June 2024. I am James Varda, CEO of Futura, and I'm joined today by Angela Hildreth, Futura's finance director and CEO, and also Ken James, executive director and Futura's head of R&D. Futura specializes in the development and commercialization of innovative sexual health care products across the board. Our lead product is a Roxxon a clinically proven breakthrough treatment for erectile dysfunction. Our key area of expertise is in topically delivered gel formulation.

Next slide. Hi, everyone. This is Ken James. Having worked my career in consumer healthcare, I can say that it is rare to have a product such as a Roxxon, which is truly unique, as it is a breakthrough, safe and effective treatment for erectile dysfunction. Why is it a breakthrough? Because of its excellent safety profile, it's available without a doctor's prescription or pharmacy consultation. This is in contrast to the oral medications known as PDE5 inhibitors, such as Viagra and Cialis, which are only available on prescription in most markets or behind the counter in the UK. Secondly, we have a fast onset of action. This means that Eroxon can be used for more spontaneous sex rather than having to wait. Thirdly, Eroxon is clinically proven in two pivotal clinical studies to be effective in mild, moderate, and severe ED in over 60% of users. And last, but certainly not least, in the dominant U.S. market, Eroxon is the first FDA-authorized ED treatment available over the counter. And we'll talk about this huge commercial opportunity later. Next slide. Let's look at the market potential for ED, which currently has a total prescription and OTC market size of $3.5 billion. As men grow older, it's a sad fact of life that things don't quite work as well, including blood flow around the body. Sometimes this can lead to heart disease and also with weight gain, type 2 diabetes. But as an early symptom, poor blood flow, you experience ED with 50% of men over 40 experiencing the problem. But also, ED is now occurring in younger men, with 14% of men between 18 and 31 experiencing the problem, often psychological as a result of performance anxiety. And this proportion in younger men seems to be growing. Also, largely as a result of the embarrassment factor, around 50% of men do not go to the doctor to seek treatment. So when you add it all up, there's huge potential for an easily accessed, safe, effective, and fast-acting treatment sold in supermarkets, pharmacies, or online. I'll now hand you back to James Barlow.